CELG
$124.09
Celgene
($.34)
(.27%)
CELG
Earnings Whisper ®
N/A
1st Quarter March 2017
Consensus:  $1.47
Revenue:  $3.06 Bil
Thursday
Apr 27
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CELG reports earnings?
Beat
Meet
Miss

Where is CELG's stock price going from here?
Up
Flat
Down
Stock chart of CELG
Analysts
Summary of analysts' recommendations for CELG
Score
Grade
Pivots
Resistance
$127.02
$126.24
$125.33

$124.55

Support
$123.64
$122.86
$121.95
Tweet
Growth
Description
Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.
Peers
Eli LillyJohnson & JohnsonRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalEndo International plcPfizerBristol-Myers SquibbInterCeptMerck & Co.